Geode Capital Management’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-72,137
| Closed | -$7.7M | – | 4562 |
|
|
2025
Q3 | $7.7M | Buy |
72,137
+3,707
| +5% | +$387K | ﹤0.01% | 2563 |
|
|
2025
Q2 | $6.47M | Buy |
68,430
+10,757
| +19% | +$796K | ﹤0.01% | 2597 |
|
|
2025
Q1 | $3.66M | Sell |
57,673
-5,068
| -8% | -$303K | ﹤0.01% | 2812 |
|
|
2024
Q4 | $2.91M | Buy |
62,741
+660
| +1% | +$24.8K | ﹤0.01% | 2993 |
|
|
2024
Q3 | $1.79M | Sell |
62,081
-3,863
| -6% | -$95.1K | ﹤0.01% | 3163 |
|
|
2024
Q2 | $954K | Buy |
65,944
+572
| +0.9% | +$8.35K | ﹤0.01% | 3325 |
|
|
2024
Q1 | $1.05M | Buy |
65,372
+4,259
| +7% | +$73.6K | ﹤0.01% | 3343 |
|
|
2023
Q4 | $1.21M | Buy |
61,113
+8,624
| +16% | +$127K | ﹤0.01% | 3277 |
|
|
2023
Q3 | $856K | Buy |
52,489
+7,497
| +17% | +$144K | ﹤0.01% | 3392 |
|
|
2023
Q2 | $951K | Buy |
44,992
+12,202
| +37% | +$260K | ﹤0.01% | 3381 |
|
|
2023
Q1 | $658K | Buy |
32,790
+1,136
| +4% | +$24.5K | ﹤0.01% | 3546 |
|
|
2022
Q4 | $827K | Sell |
31,654
-10,696
| -25% | -$142K | ﹤0.01% | 3444 |
|
|
2022
Q3 | $432K | Buy |
42,350
+27,913
| +193% | +$235K | ﹤0.01% | 3794 |
|
|
2022
Q2 | $60K | Hold |
14,437
| – | – | ﹤0.01% | 4735 |
|
|
2022
Q1 | $72K | Buy |
14,437
+1,164
| +9% | +$6.77K | ﹤0.01% | 4740 |
|
|
2021
Q4 | $89K | Buy |
13,273
+2,566
| +24% | +$13.1K | ﹤0.01% | 4759 |
|
|
2021
Q3 | $58K | Buy |
+10,707
| New | +$62.3K | ﹤0.01% | 4763 |
|
Other funds holding VRNA
Geode Capital Management's VRNA Position: Q4 2025 in Review
Geode Capital Management sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 72,137 shares — an estimated $7.7M sold.
Geode Capital Management first reported a position in VRNA in Q3 2021 and held it in 17 quarters. The position peaked at $7.7M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Geode Capital Management reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Geode Capital Management sold 72,137 Verona Pharma shares in Q4 2025, an estimated $7.7M.
- Geode Capital Management first reported a position in Verona Pharma in Q3 2021 and held it in 17 quarters.
- Geode Capital Management's Verona Pharma position peaked at $7.7M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Geode Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.